ATI vs BCPC vs LIN Stock Comparison

Ati, Balchem and Linde Prices as of Oct 26, 2026 Peers: Industry group
ATI Ati Inc
$164.50 -11.3% 1M +84.3% 1Y
Market cap
$22.65B
P/E
47.6x
Revenue (TTM)
$4.72B
Div. yield
–
Specialty Chemicals Basic Materials
3 wins
BCPC Balchem Corp
$170.62 +1.6% 1M +8.9% 1Y
Market cap
$5.35B
P/E
31.3x
Revenue (TTM)
$1.11B
Div. yield
–
Specialty Chemicals Basic Materials
4 wins
LIN Linde Plc
$507.56 +8.0% 1M +13.8% 1Y
Market cap
$235.27B
P/E
32.5x
Revenue (TTM)
$35.45B
Div. yield
0.01%
Industrial Gases Basic Materials
4 wins

Head to Head

11 decided of 12

Linde leads on 4 of the 12 questions below (Linde 4, Balchem 4, Ati 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionATIBCPCLINLeader
Larger companyMarket capitalisation $22.65B $5.35B $235.27B LIN
Cheaper on earningsLower P/E, profitable companies only 47.6x 31.3x 32.5x BCPC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 34.4x 33.1x 30.3x LIN
Faster revenue growthRevenue growth, trailing twelve months +4.6% +9.4% +6.6% BCPC
More profitableNet margin, trailing twelve months 10.1% 15.4% 20.4% LIN
Better return on capitalReturn on invested capital 14.9% 12.1% 10.8% ATI
Less leveragedLower net debt / EBITDA 1.6x 0.3x 1.8x BCPC
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% –
Better 1-year returnPrice return, last 12 months +84.3% +8.9% +13.8% ATI
Better 5-year returnAnnualised price return, 5 years +61.6%/yr +2.4%/yr +9.7%/yr ATI
Less volatileAnnualised volatility, 1 year 42.0% 20.7% 19.2% LIN
Higher overall scoreMean of the five percentile scores vs peers 58/100 67/100 59/100 BCPC

Percentile Scorecard

ATIBCPCLIN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisATIBCPCLIN
Valuation 14 #81 of 94 34 #62 of 94 20 #75 of 94
Growth 88 #12 of 92 86 #14 of 92 66 #32 of 92
Profitability 91 #9 of 89 85 #14 of 89 94 #6 of 89
Financial Health 49 #50 of 97 89 #12 of 97 52 #47 of 97
Shareholder Returns 48 #37 of 70 41 #42 of 70 64 #26 of 70
Overall 58 67 59
  • ATI ranked among 99 companies in Chemicals
  • BCPC ranked among 99 companies in Chemicals
  • LIN ranked among 99 companies in Chemicals

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodATIBCPCLINSPY
1 month -11.3%+1.6%+8.0% -0.8%
3 months -14.6%+3.5%+0.1% +3.5%
6 months +7.2%-2.6%-0.6% +7.0%
Year to date +43.3%+11.3%+19.0% +12.2%
1 year +84.3%+8.9%+13.8% +13.0%
3 years +337.6%+48.3%+37.0% +86.3%
3 years, per year +63.6%+14.0%+11.1% +23.1%
5 years +1,001.1%+12.3%+59.1% +68.6%
5 years, per year +61.6%+2.4%+9.7% +11.0%
10 years +1,052.8%+127.4%+328.1% +258.0%
10 years, per year +27.7%+8.6%+15.7% +13.6%

Risk

MeasureATIBCPCLINSPY
Volatility, 1Y 42.0%20.7%19.2% 12.7%
Downside volatility, 1Y 40.5%19.3%19.6% 12.7%
Beta vs S&P 500, 1Y 1.650.150.05 1.00
Return / volatility, 1Y 2.010.430.72 1.02
Max drawdown, 5Y -38.0%-34.1%-23.7% -25.4%
From 52-week high -29.0%-6.9%-7.1% -1.8%
52-week high $231.79$183.26$546.64 $779.14
52-week low $91.71$147.36$389.38 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleATIBCPCLIN
P/E now vs peer median 47.1xmedian 21.6x 31.7xmedian 21.6x 32.4xmedian 21.6x
P/S now vs peer median 4.8xmedian 1.4x 4.9xmedian 1.4x 6.6xmedian 1.4x
EV/EBITDA now vs peer median 26.7xmedian 12.4x 19.8xmedian 12.4x 19.5xmedian 12.4x
P/FCF now vs peer median 42.6xmedian 15.8x 30.5xmedian 15.8x 47.0xmedian 15.8x
P/B now vs peer median 11.2xmedian 1.6x 4.1xmedian 1.6x 5.8xmedian 1.6x
PEG now vs peer median 5.31median 1.66 1.68median 1.66 3.06median 1.66

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsATIBCPCLIN
Revenue $4.72B $1.11B $35.45B
Gross profit $1.10B $404.38M $17.14B
Operating income $716.80M $229.57M $9.38B
Net income $488.90M $170.85M $7.26B
Free cash flow $526.30M $178.00M $4.98B
R&D – $20.81M $146.00M
EPS (diluted) $3.44 $5.33 $15.59
Cash & equivalents $783.00M $66.26M $4.90B
Total debt $2.19B $145.94M $28.01B
Shares (diluted) 138.30M 32.03M 464.52M
Enterprise value $20.68B $5.07B $216.85B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricATIBCPCLIN
P/E 47.1x 31.7x 32.4x
P/FCF 42.6x 30.5x 47.0x
P/Operating cash flow 27.8x 24.3x 22.3x
P/S 4.8x 4.9x 6.6x
P/B 11.2x 4.1x 5.8x
P/Tangible book 11.2x 4.5x 8.1x
EV/EBITDA 26.7x 19.8x 19.5x
EV/EBIT 33.2x 24.0x 27.4x
EV/Revenue 5.0x 5.0x 7.3x
EV/FCF 45.2x 31.0x 51.7x
EV/Operating cash flow 29.6x 24.6x 24.5x
PEG (3Y EPS CAGR) 5.31 1.68 3.06

Growth

14 metrics
MetricATIBCPCLIN
Revenue growth (1Y) 4.6% 9.4% 6.6%
Revenue CAGR (3Y) 4.5% 6.2% 2.3%
Gross profit growth (1Y) 15.7% 11.4% 6.4%
Gross profit CAGR (3Y) 12.6% 11.0% 5.4%
Operating income growth (1Y) 8.8% 12.3% 5.4%
Operating income CAGR (3Y) 16.4% 14.2% 9.0%
Net income growth (1Y) 12.9% 14.5% 8.1%
Net income CAGR (3Y) 5.8% 18.3% 8.2%
EPS growth (1Y) 17.9% 16.5% 10.0%
EPS CAGR (3Y) 8.9% 18.8% 10.6%
Operating cash flow growth (1Y) 69.9% 11.0% 5.8%
Operating cash flow CAGR (3Y) – 12.3% 6.1%
Free cash flow growth (1Y) 123.6% 10.1% -1.9%
Free cash flow CAGR (3Y) – 14.8% -2.7%

Profitability

14 metrics
MetricATIBCPCLIN
Gross margin 23.4% 36.5% 48.3%
EBITDA margin 18.9% 25.1% 37.2%
Operating margin 15.2% 20.7% 26.5%
Pretax margin 12.7% 19.9% 26.4%
Net margin 10.1% 15.4% 20.4%
FCF margin 11.2% 16.1% 14.0%
Operating cash flow margin 17.1% 20.2% 29.6%
Return on equity 25.2% 13.0% 18.3%
Return on assets 8.9% 10.1% 8.4%
Return on invested capital 14.9% 12.1% 10.8%
Return on capital employed 17.6% 15.0% 13.2%
Asset turnover 0.9x 0.7x 0.4x
Cash conversion (OCF / net income) 1.6x 1.3x 1.4x
Stock comp / revenue 0.6% 1.8% 0.4%

Financial Health

11 metrics
MetricATIBCPCLIN
Debt / assets 38.2% 8.6% 31.7%
Debt / equity 1.1x 0.1x 0.7x
Net debt / EBITDA 1.6x 0.3x 1.8x
Debt / FCF 4.2x 0.8x 5.6x
Liabilities / assets 65.2% 22.1% 54.0%
Equity / assets 34.8% 77.9% 46.0%
Interest coverage – – 37.4x
Current ratio 2.3x 2.5x 0.9x
Quick ratio 1.1x 1.3x 0.7x
Cash ratio 0.6x 0.4x 0.3x
Altman Z-score 5.40 10.94 3.96

Shareholder Returns

7 metrics
MetricATIBCPCLIN
Dividend yield – 0.6% 1.2%
Net buyback yield 1.2% 2.1% 1.7%
Shareholder yield 1.2% 2.6% 3.0%
Payout ratio (earnings) – – 39.7%
Payout ratio (FCF) – – 57.8%
Dividend growth (1Y) – – 5.3%
Dividend CAGR (3Y) – – 6.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusATIBCPCLIN
Forward P/E 34.4xFY2026 33.1xFY2026 30.3xFY2026
EPS, next fiscal year $4.78FY2026 $5.15FY2026 $16.73FY2026
EPS growth, next FY +47.5%FY2026 +8.4%FY2026 +1.7%FY2026
EPS growth, the year after +23.4% +6.8% +14.2%
Revenue, next fiscal year $5.24BFY2026 $1.07BFY2026 $38.84BFY2026
Revenue growth, next FY +14.2%FY2026 +2.6%FY2026 +14.3%FY2026
Revenue growth, the year after +13.3% +9.7% -4.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersATIBCPCLIN
Held by institutions 93.5% 90.5% 85.2%
Institutions holding 785 417 2,321
Change in shares held, QoQ +0.9% +1.5% +4.2%
Institutions buying 478 193 1,213
Institutions selling 217 162 764
Buyers to sellers 2.20 1.19 1.59

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ATIBCPCLIN
ATI 1.00 0.05 -0.01
BCPC 0.05 1.00 0.25
LIN -0.01 0.25 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ATI, BCPC and LIN?

Linde (LIN) is the largest by market capitalisation: Ati (ATI) $22.65B, Balchem (BCPC) $5.35B, Linde (LIN) $235.27B.

Which stock is cheaper, ATI, BCPC and LIN?

Balchem (BCPC) trades on the lowest price-to-earnings ratio (Ati (ATI) 47.6x, Balchem (BCPC) 31.3x, Linde (LIN) 32.5x). On next year's consensus earnings, Linde (LIN) is cheapest (Ati (ATI) 34.4x, Balchem (BCPC) 33.1x, Linde (LIN) 30.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Balchem (BCPC) grew revenue fastest over the trailing twelve months: Ati (ATI) +4.6%, Balchem (BCPC) +9.4%, Linde (LIN) +6.6%.

Which company is more profitable?

Linde (LIN) has the highest net margin (Ati (ATI) 10.1%, Balchem (BCPC) 15.4%, Linde (LIN) 20.4%). On return on invested capital, Ati (ATI) leads (Ati (ATI) 14.9%, Balchem (BCPC) 12.1%, Linde (LIN) 10.8%).

Which stock has performed better?

Over the past year Ati (ATI) returned the most: Ati (ATI) +84.3%, Balchem (BCPC) +8.9%, Linde (LIN) +13.8%. Over five years, Ati (ATI) compounded fastest (Ati (ATI) +61.6%/yr, Balchem (BCPC) +2.4%/yr, Linde (LIN) +9.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Ati (ATI) 0.00%, Balchem (BCPC) 0.00%, Linde (LIN) 0.01%. Ati (ATI) and Balchem (BCPC) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Linde (LIN) has been the steadiest (Ati (ATI) 42.0%, Balchem (BCPC) 20.7%, Linde (LIN) 19.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ATI, BCPC and LIN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Linde (LIN) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.